Departamento de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Instituto de Investigación Sanitaria (IIS) La Fe, Valencia, Spain.
Australas J Dermatol. 2024 Nov;65(7):e198-e202. doi: 10.1111/ajd.14339. Epub 2024 Jun 19.
In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.
在这项原始研究中，我们根据生物制剂治疗中重度化脓性汗腺炎的疗效和安全性报告真实临床实践中的结果。结果表明，在第 16 周时，所有的活动评分和患者报告的结局均有显著改善，包括平均 IHS4 从 27.1 降至 15.6（p < 0.001）、HS-PGA 从 5.1 降至 3.2（p < 0.001）、VAS 疼痛从 8.3 降至 4.7（p < 0.001）和 DLQI 从 21.6 降至 12.6（p < 0.001）。每 2 或 4 周接受一次生物制剂治疗，耐受性良好，无停药，也未发现新的安全性问题。这些发现与在 3 期临床试验中观察到的药物有效性和良好的安全性特征相符，支持其在真实临床实践中用于治疗中重度化脓性汗腺炎。
